Sign In
Buy CRBP
$7.38
-0.160 (-2.12%)
At Close: Jun 03, 2026
Corbus Pharmaceuticals Holdings, Inc. (CRBP) Discusses Key Insights from HNSCC KOL Event Transcript
01:34pm, Monday, 01'st Jun 2026
Corbus Pharmaceuticals Holdings, Inc. (CRBP) Discusses Key Insights from HNSCC KOL Event Transcript
Corbus Pharmaceuticals Targets HPV-Linked Head and Neck Cancer With CRB-701 Study
10:05am, Monday, 01'st Jun 2026
Corbus Pharmaceuticals NASDAQ: CRBP executives and oncology specialists used an ASCO-linked discussion to outline the rationale for focusing the company's CRB-701 program on recurrent or metastatic or
Corbus Pharmaceuticals Holdings, Inc. (CRBP) Discusses Clinical Data Update From Phase 1/2 Study of CRB-701 Presented at ASCO Transcript
NORWOOD, Mass., May 26, 2026 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”) today reported updated data from its Phase 1/2 clinical study
Corbus Pharmaceuticals Teases Key ASCO Cancer Data, Late-Summer Obesity Readout
03:05am, Friday, 22'nd May 2026
Corbus Pharmaceuticals NASDAQ: CRBP Chief Executive Officer Yuval Cohen said investors should expect more mature clinical updates for CRB-701 at the upcoming ASCO meeting, including the first durabili
NORWOOD, Mass., May 21, 2026 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (Nasdaq: CRBP), a clinical-stage company focused on developing promising new therapies in oncology and obesity, t
Corbus Pharmaceuticals Appoints Pharma Industry Veteran Brent Pfeiffenberger to Board of Directors
08:00am, Thursday, 14'th May 2026
NORWOOD, Mass., May 14, 2026 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP), a clinical-stage company focused on developing promising new therapies in oncology and obesity, t
Corbus Pharmaceuticals to Participate in Upcoming Investor Conferences
07:00am, Wednesday, 13'th May 2026
NORWOOD, Mass., May 13, 2026 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (Nasdaq: CRBP), a clinical-stage company focused on developing promising new therapies in oncology and obesity, t
Corbus Pharmaceuticals Reports Q1 2026 Financial Results and Provides a Corporate Update
08:00am, Tuesday, 12'th May 2026
NORWOOD, Mass., May 12, 2026 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage company focused on developing promising new
Corbus Pharmaceuticals to Host In-Person and Virtual KOL Event at ASCO 2026
08:00am, Tuesday, 05'th May 2026
NORWOOD, Mass., May 05, 2026 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP), a clinical-stage company focused on promising new therapies in oncology and obesity, today announ
Corbus Offers Upside Despite Post-FDA Update, Analyst Highlights Competitive Edge
11:56am, Tuesday, 07'th Apr 2026
Corbus Pharmaceuticals Holdings Inc. (NASDAQ:CRBP) shares are down on Tuesday as the company announced broad alignment with the FDA regarding the registration path for its CRB-701 treatment.
Assenagon Asset Management S.A. Has $1.53 Million Holdings in Corbus Pharmaceuticals Holdings, Inc. $CRBP
03:33am, Tuesday, 31'st Mar 2026
Assenagon Asset Management S.A. increased its position in shares of Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) by 120.2% during the fourth quarter, according to the company in its most recen
How Much Upside is Left in Corbus Pharmaceuticals (CRBP)? Wall Street Analysts Think 318.33%
10:55am, Wednesday, 11'th Mar 2026
The mean of analysts' price targets for Corbus Pharmaceuticals (CRBP) points to a 318.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreemen
Corbus Pharmaceuticals Reports Q4 and 2025 Financial Results and Provides a Corporate Update
07:30am, Monday, 09'th Mar 2026
NORWOOD, Mass., March 09, 2026 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical stage company focused on promising new therapies
Corbus Pharmaceuticals to Present at the 36th Annual Oppenheimer Healthcare Life Sciences Conference
08:00am, Thursday, 12'th Feb 2026
NORWOOD, Mass., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings Inc. (NASDAQ: CRBP), a clinical-stage company focused on oncology and obesity, today announced that Yuval Cohen, Ph.D.
